Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 19/20 | 1.00 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.40 |
| ▸ | PGR | P06401 | 1/20 | 0.40 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | IDO1 | P14902 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | MAOA | P21397 | 1/20 | 0.40 |
| ▸ | CNR1 | P21554 | 1/20 | 0.40 |
| ▸ | HTR2A | P28223 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9664748 | 0.84 | CYP19A1 (0.72) | CYP19A1MEN1ALDH1A1OPRK1KMT2A | |
| SCHEMBL9965135 | 0.82 | CYP19A1 (0.70) | CYP19A1MEN1ALDH1A1MAPTMAPK1 | |
| SCHEMBL29471929 | 0.80 | CYP19A1 (0.67) | CYP19A1CYP1A1MEN1CYP17A1HPGD | |
| SCHEMBL29471935 | 0.80 | CYP19A1 (0.67) | CYP19A1CYP1A1MEN1CYP17A1HPGD | |
| SCHEMBL9945323 | 0.80 | CYP19A1 (0.68) | CYP19A1CYP17A1IDO1 | |
| SCHEMBL9945330 | 0.80 | CYP19A1 (1.00) | CYP19A1 | |
| Hydrochloric Acid SCHEMBL6005239 | 0.80 | CYP19A1 (0.67) | CYP19A1CYP1A1 | |
| SCHEMBL11015925 | 0.80 | CYP19A1 (0.67) | CYP19A1CYP1A1MEN1CYP17A1HPGD | |
| SCHEMBL29471930 | 0.80 | CYP19A1 (0.67) | CYP19A1CYP1A1MEN1CYP17A1HPGD | |
| SCHEMBL1906425 | 0.78 | CYP19A1 (0.62) | CYP19A1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 90 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8669274-B2 | Metalloenzyme inhibitor compounds | VIAMET PHARMACEUTICALS, INC. (US) | 2014-03-11 | — | — | US | disclosed |
| US-8669274-B2 | Metalloenzyme inhibitor compounds | VIAMET PHARMACEUTICALS, INC. (US) | 2014-03-11 | — | — | US | disclosed |
| WO-2012082746-A2 | METALLOENZYME INHIBITOR COMPOUNDS | VIAMET PHARMACEUTICALS, INC. (US) | 2012-06-21 | — | — | WO | disclosed |
| US-20120149729-A1 | METALLOENZYME INHIBITOR COMPOUNDS | VIAMET PHARMACEUTICALS, INC. (US) | 2012-06-14 | — | — | US | disclosed |
| US-20120149729-A1 | METALLOENZYME INHIBITOR COMPOUNDS | VIAMET PHARMACEUTICALS, INC. (US) | 2012-06-14 | — | — | US | disclosed |
| US-7132437-B2 | for example, methyl 4'-[(3,5-dibutyl-1H-1,2,4-triazol-1-yl)methyl][1,1'-biphenyl]-2-carboxylate; for treatment of congestive heart failure | G.D. SEARLE (US) | 2006-11-07 | — | — | US | disclosed |
| US-6984633-B2 | Method to treat cardiofibrosis with a combination therapy of an angiotensin II antagonist and epoxymexrenone | G.D SEARLE & CO. (US) | 2006-01-10 | — | — | US | disclosed |
| US-6858636-B2 | 1-phenyl imidazol-2-one biphenylmethyl compounds for treatment of circulatory disorders | G.D. SEARLE & CO. (US) | 2005-02-22 | — | — | US | disclosed |
| US-20040220245-A1 | for example, methyl 4'-[(3,5-dibutyl-1H-1,2,4-triazol-1-yl)methyl][1,1'-biphenyl]-2-carboxylate; for treatment of congestive heart failure | G.D. SEARLE & CO., | 2004-11-04 | — | — | US | disclosed |
| US-20040121989-A1 | such as methyl 4'-[(3,5-dibutyl-1H-1,2,4-triazol-1-yl)methyl][1,1'-biphenyl]-2-carboxylate; for treatment of congestive heart failure | G.D. SEARLE & CO. | 2004-06-24 | — | — | US | disclosed |
| WO-1992007852-A1 | BIPHENYLALKYL XANTHINE COMPOUNDS FOR TREATMENT OF CARDIOVASCULAR DISORDERS | G.D. SEARLE & CO. (US) | 1992-05-14 | — | — | WO | disclosed |
| WO-1992007834-A1 | N-SUBSTITUTED IMIDAZOL-2-ONE COMPOUNDS FOR TREATMENT OF CIRCULATORY DISORDERS | G.D. SEARLE & CO. (US) | 1992-05-14 | — | — | WO | disclosed |
| WO-1992005161-A1 | 1,3,5-TRISUBSTITUTED-1,2,4-TRIAZOLE COMPOUNDS FOR TREATMENT OF CIRCULATORY DISORDERS | G.D. SEARLE & CO. (US) | 1992-04-02 | — | — | WO | disclosed |
| US-5098920-A | Hypotensive agents and treatment of congestive heart failure | G. D. SEARLE & CO. (US) | 1992-03-24 | — | — | US | disclosed |
| WO-1992004335-A2 | RENAL-SELECTIVE BIPHENYLALKYL 1H-SUBSTITUTED-1,2,4-TRIAZOLE ANGIOTENSIN II ANTAGONISTS FOR TREATMENT OF HYPERTENSION | G.D. SEARLE & CO. (US) | 1992-03-19 | — | — | WO | disclosed |
| WO-1992002257-A2 | RENAL-SELECTIVE ANGIOTENSIN II ANTAGONISTS FOR TREATMENT OF HYPERTENSION | G.D. SEARLE & CO. (US) | 1992-02-20 | — | — | WO | disclosed |
| US-5087634-A | N-substituted imidazol-2-one compounds for treatment of circulatory disorders | G. D. SEARLE & CO. (US) | 1992-02-11 | — | — | US | disclosed |
| WO-1991019715-A1 | 1H-SUBSTITUTED-IMIDAZO[4,5-d]PYRIDAZINE COMPOUNDS FOR TREATMENT OF CARDIOVASCULAR DISORDERS | G.D. SEARLE & CO. (US) | 1991-12-26 | — | — | WO | disclosed |
| WO-1991018888-A1 | N-SUBSTITUTED-1,2,4-TRIAZOLONE COMPOUNDS FOR TREATMENT OF CARDIOVASCULAR DISORDERS | G.D. SEARLE & CO. (US) | 1991-12-12 | — | — | WO | disclosed |
| WO-1991017148-A1 | 1H-SUBSTITUTED-1,2,4-TRIAZOLE COMPOUNDS FOR TREATMENT OF CARDIOVASCULAR DISORDERS | G.D. SEARLE & CO. (US) | 1991-11-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040220245-A1 | for example, methyl 4'-[(3,5-dibutyl-1H-1,2,4-triazol-1-yl)methyl][1,1'-biphenyl]-2-carboxylate; for treatment of congestive heart failure | GLS, AGTR1, AGTR2 | CYP19A1 2608/4885CYP1A1 293/4885MEN1 3962/4885 |
| US-20040121989-A1 | such as methyl 4'-[(3,5-dibutyl-1H-1,2,4-triazol-1-yl)methyl][1,1'-biphenyl]-2-carboxylate; for treatment of congestive heart failure | GLS, AGTR1, AGTR2 | CYP19A1 3037/4885CYP1A1 307/4885MEN1 3856/4885 |
| US-20120149729-A1 | METALLOENZYME INHIBITOR COMPOUNDS | MMEL1, GPX1, MPO | CYP19A1 898/4885CYP1A1 454/4885MEN1 511/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.